Cisplatin-induced human peripheral blood mononuclear cells’ oxidative stress and nephrotoxicity in head and neck cancer patients: the influence of hydrogen peroxide
Cisplatin is a widely used antineoplastic agent in the treatment of head and neck cancer. However, it is highly nephrotoxic. Oxidative stress is the main mechanism responsible for cisplatin-induced nephrotoxicity. The aim of this study was to characterize cisplatin-induced nephrotoxicity, oxidative stress in peripheral blood mononuclear cells, and the relationship between them. Twenty-four patients were included in the study. Patients had their blood collected prior to cisplatin administration, and 5 and 20 days after initiating therapy, to assess renal function and to determine oxidative stress with MitoSOX™Red, H2DCF-DA, and Amplex® Red tests. Renal function was assessed by measuring serum creatinine, creatinine clearance, and blood urea nitrogen (BUN). Serum creatinine and creatinine clearance were used to grade nephrotoxicity using Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Compared to baseline values, the mean BUN and serum creatinine increased 135 and 100%, respectively, 5 days after cisplatin infusion. Mean creatinine clearance showed a 43% decrease compared to baseline value. Non-statistically significant changes in superoxide anion (O 2 •− ), hydrogen peroxide (H2O2), and general reactive oxygen species production occurred. A higher production of H2O2 was correlated with variation in serum creatinine, and was associated with higher grades for serum creatinine increases and creatinine clearance reductions. Linear regression analyses showed an association between H2O2 production and serum creatinine, creatinine clearance, and BUN levels. These results were observed for 5 days following cisplatin administration. In conclusion, H2O2 production was significantly related to changes in all renal parameters that were evaluated, following the cisplatin infusion.
KeywordsCisplatin Nephrotoxicity Oxidative stress Hydrogen peroxide Head and neck cancer
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Faig J, Haughton M, Taylor RC et al (2016) Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. doi: 10.1097/COC.0000000000000301 PubMedPubMedCentralGoogle Scholar
- 5.Karnofsky DA, Burchenal JH (1949) The evaluation of therapeutics in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191–205Google Scholar
- 8.Edge S, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474Google Scholar
- 11.Payne CM, Weber C, Crowley-Skillicorn C et al (2007) Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-16 colon epithelial cells. Carcinogenesis 28:215–222Google Scholar
- 15.US Department of Health and Human Services (2010) Common Terminology Criteria for Adverse Events (CTCAE). US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Version 4.0Google Scholar
- 18.Waseem M, Bhardwaj M, Tabassum H, Raisuddin S, Parvez S (2015) Cisplatin hepatotoxicity mediated by mitochondrial stress. Drug Chem Toxicol 13:1–8Google Scholar
- 23.Fuchs-Tarlovsky V, Rivera MAC, Altamirano KA, Lopez-Alvarenga JC, Ceballo-Reyes GM (2013) Antioxidant supplementation has a positive effect on oxidative stress and hematological toxicity during oncology treatment in cervical cancer patients. Support Care Cancer 21:1359–1363CrossRefPubMedGoogle Scholar
- 25.Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC (2008) Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 61:145–155CrossRefPubMedGoogle Scholar
- 26.Atessahín A, Çeribassi AO, Yuce A, Bulmus O, Çikim G (2006) Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:121–126Google Scholar
- 28.Sestakova Z, Kalavska K, Hurbanova L et al (2016) The prognostic value of DNA damage level in peripheral blood lymphocytes of chemotherapy-naïve patients with germ cell cancer. Oncotarget 46:75996–76005Google Scholar